R. Else

Low‐dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue

P. Lorigan, P. Johnson, D. Linch, 2007, British journal of haematology.

Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity

S. Salek, A. Fielding, G. Collins, 2020, Frontiers in Pharmacology.

Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study

S. Salek, A. Fielding, G. Collins, 2020, Therapeutic advances in hematology.

Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.

S. Salek, A. Fielding, G. Collins, 2019, Journal of comparative effectiveness research.

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

S. Salek, A. Fielding, G. Collins, 2020, Frontiers in Pharmacology.

Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.

S. Salek, A. Fielding, G. Collins, 2019, Journal of comparative effectiveness research.